Sumatriptan Tablet
Product Images NDC 68788-9547

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 68788-9547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
A line graph showing the estimated probability of response over time in minutes from the initial dose of Sumatriptan tablets. The graph compares placebo and Sumatriptan doses of 25 mg, 50 mg, and 100 mg, demonstrating increasing response probabilities over 240 minutes, with higher doses showing greater effects.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
A line graph showing the estimated probability of headache remediation or rescue over 24 hours from the initial dose of Sumatriptan at various dosages (placebo, 25 mg, 50 mg, and 100 mg). The x-axis represents time in hours, and the y-axis shows the estimated probability percentage.*
FDA Label Image

Sumatriptan Succinate Tablets, Usp 50mg (Sumatriptan Fig4)

Sumatriptan Succinate Tablets, Usp 50mg (Sumatriptan Fig4)
Sumatriptan Succinate Tablets USP 50 mg oral tablets labeling with generic for Imitrex. The label shows the product name, strength, manufacturer as Aurobindo Pharma, and manufacturer location N. Dayton, NJ. Includes warnings and directions in English and Spanish, barcodes, and cautionary statements about federal law prohibition on drug transfer.*
FDA Label Image

Chemical Structure (Sumatriptan Str)

Chemical Structure (Sumatriptan Str)
Chemical structure of sumatriptan succinate showing its molecular components and arrangement, including an indole ring, sulfonamide group, and succinate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.